The company’s net profit declined by 7.97% to Rs 19.04 for the quarter ended June 30, 2011 against Rs 20.69 crore in the same period previous fiscal. Total income of the company rose to Rs 182.56 crore for the June quarter, as against Rs 163.21 crore in the same period previous fiscal.
Recently, JBCPL board has granted its approval to the company for entering into a definitive agreement to sell its Russia-CIS prescription products business to Dr Reddy’s Laboratories (DRL). The transaction which involves the sale of products registration, intellectual properties, etc is for the consideration worth Rs 137.5 crore.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: